Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:CUE NASDAQ:PMN NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.56-1.0%$1.54$0.87▼$3.08$112.43M-0.321.41 million shs181,386 shsCUECue Biopharma$30.71-2.0%$245.26$4.97▼$41.42$100.52M2.37524,409 shs48,902 shsPMNPromis Neurosciences$10.53-1.4%$15.08$6.27▼$39.75$94.49M-0.2132,037 shs12,159 shsVTGNVistaGen Therapeutics$0.63-6.8%$0.60$0.43▼$5.14$24.88M0.31951,288 shs5.43 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+1.95%+14.60%-16.04%+16.30%-3.51%CUECue Biopharma-10.51%+2.96%-93.07%-89.69%-95.54%PMNPromis Neurosciences+8.65%-3.00%-15.24%-25.26%-13.92%VTGNVistaGen Therapeutics+10.34%+7.64%+20.20%+19.26%-69.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.56-1.0%$1.54$0.87▼$3.08$112.43M-0.321.41 million shs181,386 shsCUECue Biopharma$30.71-2.0%$245.26$4.97▼$41.42$100.52M2.37524,409 shs48,902 shsPMNPromis Neurosciences$10.53-1.4%$15.08$6.27▼$39.75$94.49M-0.2132,037 shs12,159 shsVTGNVistaGen Therapeutics$0.63-6.8%$0.60$0.43▼$5.14$24.88M0.31951,288 shs5.43 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+1.95%+14.60%-16.04%+16.30%-3.51%CUECue Biopharma-10.51%+2.96%-93.07%-89.69%-95.54%PMNPromis Neurosciences+8.65%-3.00%-15.24%-25.26%-13.92%VTGNVistaGen Therapeutics+10.34%+7.64%+20.20%+19.26%-69.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 2.89Moderate Buy$8.29432.84% UpsideCUECue Biopharma 1.00SellN/AN/APMNPromis Neurosciences 2.33Hold$26.50151.57% UpsideVTGNVistaGen Therapeutics 1.80Reduce$0.9551.27% UpsideCurrent Analyst Ratings BreakdownLatest VTGN, BMEA, PMN, and CUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.003/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.003/25/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/ACUECue Biopharma$27.47M3.62N/AN/A$10.08 per share3.05PMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/AVTGNVistaGen Therapeutics$490K50.78N/AN/A$2.44 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$61.80M-$1.31N/AN/AN/AN/A-305.60%-128.09%N/ACUECue Biopharma-$26.60M-$9.61N/AN/AN/A-96.85%-165.19%-77.77%N/APMNPromis Neurosciences-$39.72M-$19.00N/AN/AN/AN/A-933.63%-295.33%N/AVTGNVistaGen Therapeutics-$51.42M-$1.89N/AN/AN/AN/A-109.72%-89.62%6/16/2026 (Estimated)Latest VTGN, BMEA, PMN, and CUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/A5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/A2/12/2026Q3 2026VTGNVistaGen Therapeutics-$0.51-$0.45+$0.06-$0.45$0.14 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A5.235.23CUECue BiopharmaN/A2.742.74PMNPromis NeurosciencesN/A0.880.88VTGNVistaGen TherapeuticsN/A4.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%CUECue Biopharma35.04%PMNPromis Neurosciences50.13%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%CUECue Biopharma1.82%PMNPromis Neurosciences1.50%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5072.30 million58.98 millionOptionableCUECue Biopharma603.24 million3.18 millionOptionablePMNPromis Neurosciences58.97 million8.83 millionNot OptionableVTGNVistaGen Therapeutics4039.62 million38.49 millionOptionableVTGN, BMEA, PMN, and CUE HeadlinesRecent News About These CompaniesVistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder3 hours ago | businesswire.comVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderMay 8, 2026 | businesswire.comVistaGen Therapeutics (NASDAQ:VTGN) versus Alto Neuroscience (NYSE:ANRO) Head to Head ContrastMay 1, 2026 | americanbankingnews.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmApril 29, 2026 | globenewswire.comVistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock DropApril 28, 2026 | prnewswire.comVistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseApril 22, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmApril 20, 2026 | newsfilecorp.comNVistaGen Faces Nasdaq Audit Committee Compliance SetbackApril 2, 2026 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGNMarch 17, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMarch 16, 2026 | globenewswire.comCLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline TonightMarch 16, 2026 | businesswire.comVTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud LawsuitMarch 16, 2026 | prnewswire.comVTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMarch 16, 2026 | prnewswire.comVistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGNMarch 16, 2026 | prnewswire.comVTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNMarch 15, 2026 | newsfilecorp.comNVTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026March 15, 2026 | newsfilecorp.comNVTGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNMarch 14, 2026 | newsfilecorp.comNVTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. ...March 14, 2026 | gazettextra.comGVTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNMarch 14, 2026 | globenewswire.comVTGN UPCOMING DEADLINE ON MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action LawsuitMarch 14, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTGN, BMEA, PMN, and CUE Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.56 -0.02 (-0.96%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Cue Biopharma NASDAQ:CUE$30.70 -0.62 (-1.96%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Promis Neurosciences NASDAQ:PMN$10.53 -0.15 (-1.37%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.VistaGen Therapeutics NASDAQ:VTGN$0.63 -0.05 (-6.77%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
